Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 2529 entries
View as:

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107

Phase: N/A Priority: Normal
NCT ID: NCT00149916 Org: User:
Start: 04/30/00 End: - Due: -

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

Phase: N/A Priority: Normal
NCT ID: NCT00510354 Org: User:
Start: 10/31/06 End: 11/30/12 Due: 11/30/13

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control

Phase: N/A Priority: Normal
NCT ID: NCT01715311 Org: User:
Start: 11/30/12 End: 09/30/13 Due: 09/30/14

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03078751 Org: User:
Start: 06/20/17 End: 03/09/20 Due: 03/09/21

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02608268 Org: User:
Start: 11/23/15 End: 08/30/22 Due: 08/30/23

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT01649375 Org: User:
Start: 10/18/12 End: 09/18/18 Due: 09/18/19

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload

Phase: N/A Priority: Normal
NCT ID: NCT01254227 Org: User:
Start: 01/31/11 End: 11/30/13 Due: 11/30/14

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

Phase: N/A Priority: Normal
NCT ID: NCT01948817 Org: User:
Start: 02/28/14 End: 02/29/16 Due: 02/28/17

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase: N/A Priority: Normal
NCT ID: NCT02250443 Org: User:
Start: 03/11/14 End: 08/23/16 Due: 08/23/17

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00149981 Org: User:
Start: - End: - Due: -

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Phase: N/A Priority: Normal
NCT ID: NCT03259074 Org: User:
Start: 11/30/17 End: 11/29/21 Due: 11/29/22

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00549770 Org: User:
Start: 09/30/07 End: 07/31/08 Due: 07/31/09

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT01593527 Org: User:
Start: 09/30/12 End: 09/30/12 Due: 09/30/13

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00262990 Org: User:
Start: 11/30/05 End: - Due: -

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

Phase: N/A Priority: Normal
NCT ID: NCT01744665 Org: User:
Start: 08/12/13 End: 09/29/18 Due: 09/29/19

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

Phase: N/A Priority: Normal
NCT ID: NCT01283542 Org: User:
Start: 11/26/12 End: 09/12/17 Due: 09/12/18

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Phase: N/A Priority: Normal
NCT ID: NCT02228096 Org: User:
Start: 08/14/14 End: 05/24/19 Due: 05/24/20

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

Phase: N/A Priority: Normal
NCT ID: NCT02421172 Org: User:
Start: 04/13/15 End: 11/23/16 Due: 11/23/17

A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting

Phase: N/A Priority: Normal
NCT ID: NCT05787236 Org: User:
Start: 11/05/20 End: 03/15/22 Due: 03/15/23

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453

Phase: N/A Priority: Normal
NCT ID: NCT02052687 Org: User:
Start: 01/31/14 End: 06/30/14 Due: 06/30/15

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT05192941 Org: User:
Start: 04/08/22 End: 03/19/25 Due: 03/19/26

Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

Phase: N/A Priority: Normal
NCT ID: NCT02362789 Org: User:
Start: 01/04/15 End: 07/15/16 Due: 07/15/17

Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

Phase: N/A Priority: Normal
NCT ID: NCT00640588 Org: User:
Start: 03/31/08 End: 12/31/09 Due: 12/31/10

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04541589 Org: User:
Start: 01/05/21 End: 08/19/24 Due: 08/19/25

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Phase: N/A Priority: Normal
NCT ID: NCT05038735 Org: User:
Start: 12/17/21 End: 02/28/28 Due: 02/28/29